NCT05046080Recruiting
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 25 Aug 2021
- Start date
- 6 Aug 2021
- Primary completion date
- 29 Sept 2026
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Cervical cancer, Childhood cancers
- NCT number
- NCT05046080
What you commit to
- Study type: Observational
- Planned participants: 70
- From 6 Aug 2021 to the primary completion date, 29 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients diagnosed with clear cell carcinoma of the cervix at MDACC
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.